Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics
admin 11th June 2017 Uncategorised 0Sanofi and Regeneron still have months to wait for final data from a key cardiovascular outcomes study of their PCSK9 therapy Praluent. But the pair now has results in hand suggesting the med can safely cut “bad” cholesterol in Type 2 diabetes patients at high risk of CV problems.
More: Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics
Source: fierce